Aim: To prepare and characterize the specific monoclonal antibodies (mAbs) that can recognize the native conformation of HER2 so as to guide the clinical application of Herceptin.
Methods: Hybridomas were generated by the fusion with the NS1 myeloma cell and spleen cell, which were from mice immunized by HER2 recombinant protein. After cell fusion, ELISA, Yeast cell base ELISA and immunohistochemistry were used to screening clones respectively.
Results: Eight clones that could react with SK-Br-3 and yeast displaying HER2 were selected from 168 clones which were positive in initial screening by ELISA.
Conclusion: Successfully prepared 8 mAbs that can recognize the native conformation of HER2, which should provide useful reagent for personalized therapy against breast cancer with Herceptin.